Johnson & Johnson pharmaceutical: new drug R & D in 2019

According to the financial data disclosed by Johnson & Johnson in 2020, the company's turnover in the fourth quarter of 2019 and the whole year was 20.7 billion US dollars and 82.1 billion US dollars, respectively, up 1.7% and 0.6% year on year This paper reviews the new drug R & D events of Johnson & Johnson pharmaceutical company in 2019 by analyzing its media center On December 16, 2019, who recommended the treatment plan containing betaquiline for all types of drug-resistant tuberculosis patients On August 9, 2019, FDA approved the combination therapy containing sirturo (betaquiline) for the treatment of adult patients with MDR-TB On November 7, 2019, Johnson & Johnson pharmaceutical submitted the MAA of its Ebola virus vaccine to EMA and obtained the accelerated review status On September 3, 2019, the FDA granted breakthrough therapy certification for the prophylactic vaccine used to prevent respiratory syncytial virus infection in older adults On August 22, 2019, atlas-2m research results showed that the anti hiiv effect of long-acting injection of ribavirin and cabotegravir once every two months was equivalent to that of once a month On April 29, 2019, Janssen Pharmaceutical submitted to FDA the first two drug HIV treatment plan (ribavirin combined with cabotegravir) with monthly injection On April 11, 2019, phase 3 clinical trials of the first single therapy regimen in the rapid start care model confirmed the effectiveness and safety of symtuza for 48 weeks On December 10, 2019, the results of phase III clinical trials showed that darzalex (darzalex mAb) treatment significantly prolonged the progression free survival of patients with multiple myeloma On December 9, 2019, the results of phase III Alcyone test showed that for newly diagnosed multiple myeloma patients who are not suitable for stem cell transplantation, darzalex can bring total survival benefit and continue to improve the progression free survival of patients, so as to make darzalex It is the first CD38 targeted antibody that has been proved to bring total survival benefit to patients with multiple myeloma On September 26, 2019, the FDA approved the combination of darzalex (darzalex mAb) for the treatment of newly diagnosed patients with multiple myeloma who can undergo stem cell transplantation, so that darzalex (darzalex mAb) became the first biological product approved by the FDA for the treatment of this indication population This is also the seventh indication approved by darzalex On July 12, 2019, Janssen Pharmaceutical submitted a new drug application for darzalex subcutaneous injection to FDA Previously, the results of phase 3 Columba test published on June 3, 2019 confirmed that the efficacy of darzalex (darzalex mAb) subcutaneously injected to patients with multiple myeloma of relapse and refractory type was not inferior to its intravenous injection, which had been approved by FDA on November 16, 2015 On June 27, 2019, the FDA approved darzalex (darzalezumab) in combination with lenalidomide and dexamethasone for the treatment of newly diagnosed multiple myeloma patients who could not receive stem cell transplantation On June 3, 2019, darzalex study confirmed that for newly diagnosed multiple myeloma patients suitable for stem cell transplantation, darzalex can improve the depth of remission and prolong the progression free survival period On May 29, 2019, the results of the phase 3 Maia study of darzalex ® (darzalex mAb) published in the Journal of the New England Journal of Medicine showed that the combination therapy can prolong the progression free survival of newly diagnosed multiple myeloma patients who are not suitable for stem cell transplantation On February 12, 2019, FDA approved darzalex (darzalex mAb) in a dose-dependent manner On December 9, 2019, Yang Sen acquired bermekimab from xbiotech Bermekimab is in the stage of clinical research and is the first anti-il-ia antibody in the world for the treatment of idiopathic dermatitis and pyogenic sweat adenitis On December 9, 2019, the data of imbruvica (ebtinib) combined medication published by the American Society of Hematology (ash) at its annual meeting in 2019 from two studies and long-term comprehensive analysis confirmed the safety and effectiveness of the drug as the first-line treatment of lymphoid leukemia On June 3, 2019, the long-term data of two key phase 3 clinical trials published by Johnson & Johnson pharmaceutical in ASCO and EHA confirmed the continuous effectiveness and safety of imbruvica in patients with chronic lymphocytic leukemia On January 28, 2019, the FDA approved imbruvica (ebtinib) combined with obinutuzumab as the first non chemotherapy combination therapy for patients with chronic lymphoblastic leukemia who had not been treated before On April 15, 2019, the FDA approved balfersa Gamma Erdafitinib is used to treat locally advanced or metastatic urothelial carcinoma with a specific FGFR genetic mutation BCMA car-t therapy jnj-4528 On December 9, 2019, the results of cartitude-1 test in phase I B / 2 showed that jnj-4528 could produce early, deep and high remission effects in the treatment of multiple myeloma with relapse or refractory type On December 9, 2019, based on the results of cartitude-1 test, FDA awarded jnj-4528 as a safe treatment for multiple myeloma with relapse or refractory type On November 12, 2019, the latest analysis results of landmark credence test data showed that the efficacy and safety characteristics of cagregyne were the same in patients with various liver function levels Cagreggin is the first antidiabetic drug to slow the progression of diabetic nephropathy in type 2 diabetic patients and reduce the risk of hospitalization for heart failure in type 2 diabetic patients with diabetic nephropathy On September 30, 2019, the FDA approved invokana to be used in the treatment of diabetic nephropathy in patients with type 2 diabetes mellitus and diabetic nephropathy, and to reduce the risk of hospitalization due to heart failure On June 11, 2019, the latest credence analysis results show that invokana can significantly reduce the risk of major cardiovascular events and renal failure in patients with type 2 diabetes mellitus and chronic kidney disease On November 11, 2019, the results of discover-1 and discover-2 research published at the annual meeting of American rheumatology society and rheumatology professional association in 2019 showed that the ACR20 remission rate of tremfya (guselkumab), the first IL-23 P19 subunit inhibitor in the world, was better than that of placebo (main clinical end point) in patients with psoriatic arthritis in the 24th week On February 27, 2019, FDA approved tremfya (guselkumab) single pressure patient control syringe for the treatment of adult patients with moderate to severe plaque psoriasis On October 21, 2019, FDA approved stelara ® (ulinumab) for the treatment of moderate to severe active ulcers Stelara ® (ulinumab) is the first and only drug approved for the treatment of ulcerative colitis and may improve the colon function according to the new histological endoscopic end point of mucosal improvement On October 21, 2019, new data showed that maxitan combined with tadalafil could improve the clinical and functional parameters of hemodynamics in patients with pulmonary hypertension Specifically, the average pulmonary vascular resistance at the 16th week decreased by 47% compared with the baseline On March 15, 2019, the interim analysis showed that opsumit could significantly improve the right ventricular function and pulmonary vascular resistance in patients with pulmonary hypertension In October 18, 2019, Spravato (esketamine) nasal spray was used to treat MAA in adult patients with refractory severe depressive disorder and received positive opinions on CHMP If approved, spravato (esketamine) will become the first major depression treatment drug with a new mechanism within 30 years In October 2, 2019, Yang Sen submitted Spravato to (FDA) nasal spray for NDA to reduce NDA in depressed adults with active Dutch act depression If approved, Spravato (esketamine) nasal spray will be the first drug used for this adaptive population In March 5, 2019, FDA approved SPRAVATOTM (esketamine) CIII nasal spray for the treatment of resistant adults with depression On October 14, 2019, the FDA approved xarelto (rivaroxaban) to prevent blood clots in severe patients On September 20, 2019, real world research results show that xarelto can reduce the total medical cost of recurrent blood clots and diseases in obese patients On July 8, 2019, the results of the phase 3 einstein-jr study showed that xarelto (rivaroxaban) could help prevent blood clots in pediatric patients On March 18, 2019, real world research results showed that xarelto significantly reduced the risk of overall stroke and the most severe stroke in patients with nonvalvular atrial fibrillation compared with warfarin, and the risk of stroke related death in xarelto was lower than warfarin On March 11, 2019, a large-scale real world meta-analysis of oral anticoagulants with non vitamin K antagonists showed that xarelto (rivaroxaban) significantly reduced the risk of ischemic stroke in patients with non valvular atrial fibrillation On October 3, 2019, the FDA granted breakthrough therapy certification to niraparib for the treatment of metastatic castrated resistant prostate cancer On September 27, 2019, the updated results of the Spartan trial published at the annual meeting of the European Society of Oncology (ESMO) in 2019 and published in annals of oncology show that erleada (apalutamine) can reduce the risk of death in patients with non metastatic castrated and resistant prostate cancer by 25% On September 19, 2019, the FDA approved erleada (apalutamine) as a supplementary NDA for the treatment of metastatic castrated resistant prostate cancer The phase 3 Titan trial, which is the basis of this approval, is the first registered study to improve the overall and imaging progression free survival of patients with metastatic castrated prostate cancer in various conditions On May 31, 2019, phase 3 clinical trials confirmed that erleada (apalutamine) can significantly improve the overall survival and imaging progression free survival of patients with metastatic castrated resistant prostate cancer On April 29, 2019, Janssen Pharmaceutical submitted erleada (apalutamine) to FDA for the treatment of metastatic castration sensitive prostate cancer On September 11, 2019, the head-to-head phase 3 optimum test published at the 35th session of the European Commission for multiple sclerosis treatment and research confirmed that ponesimod is more effective than aubagio in patients with multiple sclerosis